EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The controversial role of metabolic reprogramming in anti-tumor therapy resistance

Yaolin Xu, Yuqing Wang, Qiang Fu, Yuan Yao, Yubin Zhou

Discover Oncology · 15.03.2026 · 17 (1)

DOI: 10.1007/s12672-026-04787-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 15.03.2026. Verfasst von Yaolin Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Medicine, The People's Hospital of China Medical University/The People's Hospital of LiaoNing Province, No. 33 Wenyi Roa…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Joint General Program project of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-tumor therapies, including chemotherapy, immunotherapy, targeted therapy and endocrine therapy highlight an increasingly important role, but drug resistance limits their efficacy. In the nutrient-poor tumor microenvironment (TME), tumor cells resist the anti-tumor therapies by turning into ‘resistance continuum’. Metabolic reprogramming serves an essential character in the cellular ‘resistance continuum’. The process of metabolic reprogramming is heterogeneous, dynamic and complex in drug-resistant tumor cells. Some resist the killing effects of anti-tumor drugs by enhancing glycolysis, some by heightening lipid metabolism, some by boosting amino acid metabolism, and some even by potentiating OXPHOS which is contrary to the traditional Warburg effect. These metabolic reprogrammed processes could help tumor cells to maintain intracellular redox homeostasis and evade ferroptosis under anti-tumor treatments. This review has attempted to describe the common mechanisms in drug-resistant tumor cells under chemotherapy, immunotherapy, targeted therapy and endocrine therapy from the perspective of metabolic reprogramming, and summarizes recent advances in research on targeting metabolism to overcome drug resistance.

Schlagwörter

Stichwörter der Autor:innen

Drug resistanceFerroptosisGlycolysisMetabolic reprogrammingOXPHOS

Autor:innen und Institutionen

  • Department of Interventional Medicine, The People's Hospital of China Medical University/The People's Hospital of LiaoNing Province, No. 33 Wenyi Road, Shenhe District, Shenyang, China.
  • The Fourth Clinical College, China Medical University, Shenyang, China.
  • Department of Cardiology, The People's Hospital of China Medical University/The People's Hospital of LiaoNing Province, Shenyang, China.
  • Department of Interventional Medicine, The People's Hospital of China Medical University/The People's Hospital of LiaoNing Province, No. 33 Wenyi Road, Shenhe District, Shenyang, China. yaoyuan-621@163.com.
  • Department of Interventional Medicine, The People's Hospital of China Medical University/The People's Hospital of LiaoNing Province, No. 33 Wenyi Road, Shenhe District, Shenyang, China. zhouyubin2025@126.com.

Förderung

  • Joint General Program project of Liaoning Province

Zitieren

APA

Xu, Y., Wang, Y., Fu, Q., Yao, Y., & Zhou, Y. (2026). The controversial role of metabolic reprogramming in anti-tumor therapy resistance. Discover Oncology, 17(1). https://doi.org/10.1007/s12672-026-04787-7

Vancouver

Xu Y, Wang Y, Fu Q, Yao Y, Zhou Y. The controversial role of metabolic reprogramming in anti-tumor therapy resistance. Discover Oncology. 2026;17(1). doi:10.1007/s12672-026-04787-7

BibTeX
@article{Xu2026,
  author = {Xu, Yaolin and Wang, Yuqing and Fu, Qiang and Yao, Yuan and Zhou, Yubin},
  title = {The controversial role of metabolic reprogramming in anti-tumor therapy resistance},
  journal = {Discover Oncology},
  year = {2026},
  volume = {17},
  number = {1},
  doi = {10.1007/s12672-026-04787-7}
}
Kostenlos starten →